Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study

J. Thomas Hutton; Leo Verhagen Metman; Thomas N. Chase; Jorge L. Juncos; William C. Koller; Rajesh Pahwa; Peter A. LeWitt; Ali Samii; Joseph K.C. Tsui; Donald B. Calne; Cheryl H. Waters; Vincent P. Calabrese; James P. Bennett; Richard Barrett; Jerry L. Morris

doi:10.1002/mds.1085

Transdermal dopaminergic D₂ receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study

J. Thomas Hutton^*, Leo Verhagen Metman, Thomas N. Chase, Jorge L. Juncos, William C. Koller, Rajesh Pahwa, Peter A. LeWitt, Ali Samii, Joseph K.C. Tsui, Donald B. Calne, Cheryl H. Waters, Vincent P. Calabrese, James P. Bennett, Richard Barrett, Jerry L. Morris

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Abstract

N-0923 is a non-ergot, dopaminergic D₂ agonist designed to be transdermally available. It has anti-parkinsonian effects when infused intravenously. An adhesive matrix patch was developed to deliver N-0923 transdermally (N-0923 TDS). In this phase II trial, we evaluated the effectiveness of various doses of N-0923 TDS at replacing levodopa. Eighty-five Parkinson's disease (PD) patients were randomized to placebo or one of four doses of N-0923 TDS for 21 days. Change in daily levodopa dose was the primary efficacy measure. Significantly greater reductions in levodopa dose were achieved as compared to placebo for the two highest doses of N-0923 TDS. Patients treated with 33.5 mg and 67 mg N-0923 TDS decreased levodopa use by 26% and 28%, vs. 7% for placebo. N-0923 TDS was safe and well tolerated.

Original language	English (US)
Pages (from-to)	459-463
Number of pages	5
Journal	Movement Disorders
Volume	16
Issue number	3
DOIs	https://doi.org/10.1002/mds.1085
State	Published - May 2001

Keywords

Dopaminergic D agonist
N-0923 transdermal
Parkinson's disease

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/mds.1085

Cite this

Hutton, J. T., Metman, L. V., Chase, T. N., Juncos, J. L., Koller, W. C., Pahwa, R., LeWitt, P. A., Samii, A., Tsui, J. K. C., Calne, D. B., Waters, C. H., Calabrese, V. P., Bennett, J. P., Barrett, R., & Morris, J. L. (2001). Transdermal dopaminergic D₂ receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study. Movement Disorders, 16(3), 459-463. https://doi.org/10.1002/mds.1085

@article{ca1116e244ff4f8b8ec3e0ec28e5f0a0,

title = "Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study",

abstract = "N-0923 is a non-ergot, dopaminergic D2 agonist designed to be transdermally available. It has anti-parkinsonian effects when infused intravenously. An adhesive matrix patch was developed to deliver N-0923 transdermally (N-0923 TDS). In this phase II trial, we evaluated the effectiveness of various doses of N-0923 TDS at replacing levodopa. Eighty-five Parkinson's disease (PD) patients were randomized to placebo or one of four doses of N-0923 TDS for 21 days. Change in daily levodopa dose was the primary efficacy measure. Significantly greater reductions in levodopa dose were achieved as compared to placebo for the two highest doses of N-0923 TDS. Patients treated with 33.5 mg and 67 mg N-0923 TDS decreased levodopa use by 26% and 28%, vs. 7% for placebo. N-0923 TDS was safe and well tolerated.",

keywords = "Dopaminergic D agonist, N-0923 transdermal, Parkinson's disease",

author = "Hutton, {J. Thomas} and Metman, {Leo Verhagen} and Chase, {Thomas N.} and Juncos, {Jorge L.} and Koller, {William C.} and Rajesh Pahwa and LeWitt, {Peter A.} and Ali Samii and Tsui, {Joseph K.C.} and Calne, {Donald B.} and Waters, {Cheryl H.} and Calabrese, {Vincent P.} and Bennett, {James P.} and Richard Barrett and Morris, {Jerry L.}",

year = "2001",

month = may,

doi = "10.1002/mds.1085",

language = "English (US)",

volume = "16",

pages = "459--463",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

Hutton, JT, Metman, LV, Chase, TN, Juncos, JL, Koller, WC, Pahwa, R, LeWitt, PA, Samii, A, Tsui, JKC, Calne, DB, Waters, CH, Calabrese, VP, Bennett, JP, Barrett, R & Morris, JL 2001, 'Transdermal dopaminergic D₂ receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study', Movement Disorders, vol. 16, no. 3, pp. 459-463. https://doi.org/10.1002/mds.1085

TY - JOUR

T1 - Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS

T2 - A double-blind, placebo-controlled study

AU - Hutton, J. Thomas

AU - Metman, Leo Verhagen

AU - Chase, Thomas N.

AU - Juncos, Jorge L.

AU - Koller, William C.

AU - Pahwa, Rajesh

AU - LeWitt, Peter A.

AU - Samii, Ali

AU - Tsui, Joseph K.C.

AU - Calne, Donald B.

AU - Waters, Cheryl H.

AU - Calabrese, Vincent P.

AU - Bennett, James P.

AU - Barrett, Richard

AU - Morris, Jerry L.

PY - 2001/5

Y1 - 2001/5

N2 - N-0923 is a non-ergot, dopaminergic D2 agonist designed to be transdermally available. It has anti-parkinsonian effects when infused intravenously. An adhesive matrix patch was developed to deliver N-0923 transdermally (N-0923 TDS). In this phase II trial, we evaluated the effectiveness of various doses of N-0923 TDS at replacing levodopa. Eighty-five Parkinson's disease (PD) patients were randomized to placebo or one of four doses of N-0923 TDS for 21 days. Change in daily levodopa dose was the primary efficacy measure. Significantly greater reductions in levodopa dose were achieved as compared to placebo for the two highest doses of N-0923 TDS. Patients treated with 33.5 mg and 67 mg N-0923 TDS decreased levodopa use by 26% and 28%, vs. 7% for placebo. N-0923 TDS was safe and well tolerated.

AB - N-0923 is a non-ergot, dopaminergic D2 agonist designed to be transdermally available. It has anti-parkinsonian effects when infused intravenously. An adhesive matrix patch was developed to deliver N-0923 transdermally (N-0923 TDS). In this phase II trial, we evaluated the effectiveness of various doses of N-0923 TDS at replacing levodopa. Eighty-five Parkinson's disease (PD) patients were randomized to placebo or one of four doses of N-0923 TDS for 21 days. Change in daily levodopa dose was the primary efficacy measure. Significantly greater reductions in levodopa dose were achieved as compared to placebo for the two highest doses of N-0923 TDS. Patients treated with 33.5 mg and 67 mg N-0923 TDS decreased levodopa use by 26% and 28%, vs. 7% for placebo. N-0923 TDS was safe and well tolerated.

KW - Dopaminergic D agonist

KW - N-0923 transdermal

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0035353743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035353743&partnerID=8YFLogxK

U2 - 10.1002/mds.1085

DO - 10.1002/mds.1085

M3 - Article

C2 - 11391739

AN - SCOPUS:0035353743

SN - 0885-3185

VL - 16

SP - 459

EP - 463

JO - Movement Disorders

JF - Movement Disorders

IS - 3

ER -